National Natural Science Foundation Project: "Synthesis of Rosin Resin Acid Derivatives and Study on Structure-Activity Relationship of Antitumor Activity (No.3077 1690)", "study on novel GABA transporters on blood-brain barrier (No.30 17 1075)" and "the relationship between drug transport in brain and p-glycoprotein on blood-brain barrier" (No.China postdoctoral science fund project). "Screening of P- glycoprotein inhibitors in natural products and study on their improvement and mechanism in the treatment of brain tumors" and "Study on the relationship between proanthocyanidins regulating P- glycoprotein in blood-brain barrier and its anti-cerebral ischemia effect and target pathway" (No ZJ 1005), The national forestry administration's agricultural scientific and technological achievements transformation fund project "Extraction and separation of bioactive components from pine needles and study on their biological activities (No.2008GB243204 12)", the natural science fund project of Jiangsu Province "Study on the therapeutic effect of P- glycoprotein inhibitor on transplanted human brain tumor in nude mice (NOBK 2041KLOC-0/0)" and Jiangsu Province.
9 patents have been applied for related research, 2 patents have been granted, more than 40 academic papers have been published in domestic and foreign journals, and 25 academic papers have been included in SCI. The research results won the Shiweiya Young Pharmacologist Award, the first prize of Jiangsu Science and Technology Progress Award, and the 20 10 New Century Excellent Talents Project of the Ministry of Education.
The research direction mainly focuses on the therapeutic target mechanism of Alzheimer's disease (AD) and the research and development of new drugs, mainly focusing on the following three aspects:
1) to systematically study and clarify the relationship between the regulation of polyterpene metabolism in the brain and the function and expression of P- glycoprotein (P-gp) on the blood-brain barrier and the pathogenesis and treatment of AD, so as to provide new research directions and ideas for exploring the etiology and pathological mechanism of AD and provide clues and experimental basis for finding new targets of AD prevention and treatment drugs. Alzheimer's disease is a common chronic progressive neurodegenerative disease in the elderly. There are few drugs that are effective for AD, and there is no drug that can cure AD radically. The research on the target of AD prevention and treatment has become an international hotspot. Our previous research found that the abnormal level of polyterpenoid alcohol in the brain is closely related to the pathogenesis of AD, and polyterpenoid alcohol may become a new target for the prevention and treatment of AD. Regulating the metabolism of polyterpenoids in the brain may provide a new way for the prevention and treatment of AD.
2) Relying on the "Twelfth Five-Year Plan" major project of new drug creation "Establishment of a new G-protein-coupled receptor targeted drug screening system and research on its key technologies", a stable GPCR cell line and its Qualcomm screening model were established around the G-protein-coupled receptor (GPCRS) related to AD treatment, so as to realize the innovation of new drug screening technology for G-protein-coupled receptor and establish a multi-level new drug screening model for AD treatment, providing a new screening technology platform for promoting the research and development of new drugs for AD treatment.
3) To carry out preclinical research on the innovative drug Pinus massoniana needle polyprenol for the treatment of Alzheimer's disease. Polypentenol is a long-chain terpenoid. The needles of Pinus massoniana contain about 65438 0% polyprenol, which is an ideal raw material for preparing polyprenol. The preliminary pharmacodynamic study of our group shows that needle-like polyprenol has obvious anti-AD effect and has a good prospect of being developed as an innovative drug for treating AD.
In addition, as the main research member of the project, he has participated in three major special projects of 863 of the Ministry of Science and Technology: "Establishing a new drug screening model in Qualcomm (No.2001A234011)" and "New Qualcomm drug screening model, compound library construction and drug screening (No.2004AA2Z3785).
Participated in the completion of the "863" three special projects of the Ministry of Science and Technology. In 2003, he won the Schwiya Young Pharmacologist Award of the Seventh Chinese Pharmacological Society and the first prize of Jiangsu Science and Technology Progress Award in 2006. Over the years, as editor-in-chief and deputy editor-in-chief, he has published 4 monographs and participated in 3.